Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials
Andreas Wollenberg(University Hospital Augsburg), Jacob P. Thyssen(Bispebjerg Hospital), Eric L. Simpson(Oregon Health & Science University), Mark Boguniewicz(University of Colorado Denver), Shinichi Imafuku, Lisa A. Beck(University of Rochester Medicine), C.K. Olsen(Leo Pharma (Denmark)), Rebecca Zachariae(Leo Pharma (Denmark)), Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases)
Cited by 85
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k